Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

direct rx - dicyclomine hydrochloride (unii: cq903kqa31) (dicyclomine - unii:4kv4x8if6v) - dicyclomine hydrochloride is indicated for the treatment of patients with functional bowel/irritable bowel syndrome 5.2 cardiovascular conditions dicyclomine hydrochloride needs to be used with caution in conditions characterized by tachyarrhythmia such as thyrotoxicosis, congestive heart failure and in cardiac surgery, where they may further accelerate the heart rate. investigate any tachycardia before administration of dicyclomine hydrochloride. care is required in patients with coronary heart disease, as ischemia and infarction may be worsened, and in patients with hypertension [see  adverse reactions ( 6.3)]. 5.3 peripheral and central nervous system the peripheral effects of dicyclomine hydrochloride are a consequence of their inhibitory effect on muscarinic receptors of the autonomic nervous system. they include dryness of the mouth with difficulty in swallowing and talking, thirst, reduced bronchial secretions, dilatation of the pupils (mydriasis) with loss of accommodation (cyc

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - dicyclomine hydrochloride (unii: cq903kqa31) (dicyclomine - unii:4kv4x8if6v) - dicyclomine hydrochloride is indicated for the treatment of patients with functional bowel/irritable bowel syndrome. dicyclomine hydrochloride is contraindicated in infants less than 6 months of age [see  use in specific populations ( 8.4)] , nursing mothers [see  use in specific populations ( 8.3)] , and in patients with: - unstable cardiovascular status in acute hemorrhage - myasthenia gravis [see  warnings and precautions ( 5.4)] - glaucoma [see  adverse reactions ( 6.3) and  drug interactions  ( 7.1)] - obstructive uropathy [see  warnings and precautions ( 5.8)] - obstructive disease of the gastrointestinal tract [see  warnings and precautions ( 5.5)]

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - dicyclomine hydrochloride (unii: cq903kqa31) (dicyclomine - unii:4kv4x8if6v) - dicyclomine hydrochloride is indicated for the treatment of patients with functional bowel/irritable bowel syndrome. dicyclomine hydrochloride is contraindicated in infants less than 6 months of age [see use in specific populations (8.4)] , nursing mothers [see use in specific populations (8.3)] and in patients with: adequate and well-controlled studies have not been conducted with dicyclomine in pregnant women at the recommended doses of 80 mg/day to 160 mg/day. however, epidemiologic studies did not show an increased risk of structural malformations among babies born to women who took products containing dicyclomine hydrochloride at doses up to 40 mg/day during the first trimester of pregnancy. reproduction studies have been performed in rats and rabbits at doses up to 33 times the maximum recommended human dose based on 160 mg/day (3 mg/kg) and have revealed no evidence of harm to the fetus due to dicyclomine. because animal reproduction studies are not always predictive of human response, this drug shoul

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

redpharm drug, inc. - dicyclomine hydrochloride (unii: cq903kqa31) (dicyclomine - unii:4kv4x8if6v) - dicyclomine hydrochloride is indicated for the treatment of patients with functional bowel/irritable bowel syndrome. dicyclomine hydrochloride is contraindicated in infants less than 6 months of age [see use in specific populations (8.4)], nursing mothers [see use in specific populations (8.3)], and in patients with: unstable cardiovascular status in acute hemorrhage myasthenia gravis [see warnings and precautions (5.4)] glaucoma [see adverse reactions (6.3) and drug interactions (7.1)] obstructive uropathy [see warnings and precautions (5.8)] obstructive disease of the gastrointestinal tract [see warnings and precautions (5.5)] severe ulcerative colitis [see warnings and precautions (5.7)] reflux esophagitis 8.1 pregnancy teratogenic effects: pregnancy category b adequate and well-controlled studies have not been conducted with dicyclomine hydrochloride in pregnant women at the recommended doses of 80 to 160 mg/day. however, epidemiologic studies did not show an increased r

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - dicyclomine hydrochloride (unii: cq903kqa31) (dicyclomine - unii:4kv4x8if6v) - dicyclomine hydrochloride is indicated for the treatment of patients with functional bowel/irritable bowel syndrome. dicyclomine hydrochloride is contraindicated in infants less than 6 months of age [see  use in specific populations ( 8.4)] , nursing mothers [see  use in specific populations ( 8.3)] , and in patients with: - unstable cardiovascular status in acute hemorrhage - myasthenia gravis [see  warnings and precautions ( 5.4)] - glaucoma [see  adverse reactions ( 6.3) and  drug interactions  ( 7.1)] - obstructive uropathy [see  warnings and precautions ( 5.8)] - obstructive disease of the gastrointestinal tract [see  warnings and precautions ( 5.5)]

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - dicyclomine hydrochloride (unii: cq903kqa31) (dicyclomine - unii:4kv4x8if6v) - dicyclomine hydrochloride is indicated for the treatment of patients with functional bowel/irritable bowel syndrome. dicyclomine hydrochloride is contraindicated in infants less than 6 months of age [see  use in specific populations ( 8.4)] , nursing mothers [see  use in specific populations ( 8.3)] , and in patients with: - unstable cardiovascular status in acute hemorrhage - myasthenia gravis [see  warnings and precautions ( 5.4)] - glaucoma [see  adverse reactions ( 6.3) and  drug interactions  ( 7.1)] - obstructive uropathy [see  warnings and precautions ( 5.8)] - obstructive disease of the gastrointestinal tract [see  warnings and precautions ( 5.5)]

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

remedyrepack inc. - dicyclomine hydrochloride (unii: cq903kqa31) (dicyclomine - unii:4kv4x8if6v) - dicyclomine hydrochloride is indicated for the treatment of patients with functional bowel/irritable bowel syndrome. dicyclomine hydrochloride is contraindicated in infants less than 6 months of age [see  use in specific populations ( 8.4)] , nursing mothers [see  use in specific populations ( 8.3)] , and in patients with: - unstable cardiovascular status in acute hemorrhage - myasthenia gravis [see  warnings and precautions ( 5.4)] - glaucoma [see  adverse reactions ( 6.3) and  drug interactions  ( 7.1)] - obstructive uropathy [see  warnings and precautions ( 5.8)] - obstructive disease of the gastrointestinal tract [see  warnings and precautions ( 5.5)]

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

quality care products, llc - dicyclomine hydrochloride (unii: cq903kqa31) (dicyclomine - unii:4kv4x8if6v) - dicyclomine hydrochloride is indicated for the treatment of patients with functional bowel/irritable bowel syndrome. dicyclomine hydrochloride is contraindicated in infants less than 6 months of age [see use in specific populations (8.4)] , nursing mothers [see use in specific populations (8.3)] , and in patients with: - unstable cardiovascular status in acute hemorrhage - myasthenia gravis [see warnings and precautions (5.4)] - glaucoma [see adverse reactions (6.3) and drug interactions  (7.1)] - obstructive uropathy [see warnings and precautions (5.8)] - obstructive disease of the gastrointestinal tract [see warnings and precautions (5.5)] - severe ulcerative colitis [see warnings and precautions (5.7)] - reflux esophagitis teratogenic effects: pregnancy category b adequate and well-controlled studies have not been conducted with dicyclomine hydrochloride in pregnant women at the recommended doses of 80 to 160 mg/day. however, epidemiologic studies did not show an increased risk of structural malform

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

denton pharma, inc. dba northwind pharmaceuticals - dicyclomine hydrochloride (unii: cq903kqa31) (dicyclomine - unii:4kv4x8if6v) - dicyclomine hydrochloride is indicated for the treatment of patients with functional bowel/irritable bowel syndrome. dicyclomine hydrochloride is contraindicated in infants less than 6 months of age [see  use in specific populations ( 8.4)] , nursing mothers [see  use in specific populations ( 8.3)] , and in patients with: - unstable cardiovascular status in acute hemorrhage - myasthenia gravis [see  warnings and precautions ( 5.4)] - glaucoma [see  adverse reactions ( 6.3) and  drug interactions  ( 7.1)] - obstructive uropathy [see  warnings and precautions ( 5.8)] - obstructive disease of the gastrointestinal tract [see  warnings and precautions ( 5.5)]

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

denton pharma, inc. dba northwind pharmaceuticals - dicyclomine hydrochloride (unii: cq903kqa31) (dicyclomine - unii:4kv4x8if6v) - dicyclomine hydrochloride is indicated for the treatment of patients with functional bowel/irritable bowel syndrome. dicyclomine hydrochloride is contraindicated in infants less than 6 months of age [see  use in specific populations ( 8.4)] , nursing mothers [see  use in specific populations ( 8.3)] , and in patients with: - unstable cardiovascular status in acute hemorrhage - myasthenia gravis [see  warnings and precautions ( 5.4)] - glaucoma [see  adverse reactions ( 6.3) and  drug interactions  ( 7.1)] - obstructive uropathy [see  warnings and precautions ( 5.8)] - obstructive disease of the gastrointestinal tract [see  warnings and precautions ( 5.5)]